14 Apr. 2026

Adimmune Adds Third GMP Production Line Focused on High-Value, Small-Batch Manufacturing

Adimmune Corporation (TWSE: 4142) today announced that its newly expanded third automated aseptic filling line has passed inspection by Taiwan’s Food and Drug Administration and has been certified as compliant with Good Manufacturing Practice (GMP). The new line utilizes single-use disposable filling assemblies, enabling high-value, small-batch, and diversified production.

17 Mar. 2026

Strong Growth Outlook Drives 150% Oversubscription of Adimmune’s Syndicated Loan

Adimmune Corporation (TWSE: 4142) today signed a NT$4.5 billion syndicated loan agreement with a consortium of ten banks led by Land Bank of Taiwan. Reflecting strong confidence in Adimmune’s growth prospects and recognition of vaccines as a strategically critical industry, the facility was oversubscribed by 150%, demonstrating robust support from the financial sector.

06 Feb. 2026

Did you know the 1,000 Japanese yen banknote hides a story about the Tetanus Vaccine?

When traveling in Japan, everyone is surely familiar with the 1,000 yen banknote.
The dignified gentleman featured on it is Shibasaburō Kitasato, widely regarded as the “Father of Modern Japanese Medicine”—and a pioneer in therapeutic medicine who helped change the course of human history.
1889: Became the world’s first scientist to successfully culture Clostridium tetani, the bacterium that causes tetanus.

14 Jan. 2026

Enimmune’s Enterovirus Vaccine Obtains Vietnam GMP Certification

Enimmune Corp. (TPEx: 6564), an Adimmune Corporation’s subsidiary, announced yesterday through a material information disclosure that it has obtained Vietnam GMP certification for its Enterovirus 71 (EV71) vaccine, EnVAX-A71, which is manufactured at Adimmune’s Tanzi Cell Culture Plant. The certification has been officially published on the website of the Drug Administration of Vietnam (DAV) and Adimmune (TWSE: 4142) is included in the list of GMP-compliant foreign manufacturing facilities.

19 Dec. 2025

Adimmune Celebrates 60th Anniversary with Community-Focused Charity Event

Adimmune Corporation (TWSE: 4142) marked its 60th anniversary yesterday with a charity Christmas fair held in Tanzi District, Taichung, reaffirming the Company’s long-standing commitment to community engagement, public health, and sustainable development.

17 Dec. 2025

Adimmune and Enimmune Receive Gold Award for Corporate Epidemic Prevention; Recognized Among Top 10 Vaccine News of 2025

Adimmune Corporation (TWSE: 4142) today announced that both Adimmune and its subsidiary, Enimmune Corp. (TWSE: 6564), have been honored with the Gold Award for Corporate Epidemic Prevention, and recognized among the Top 10 Vaccine News of 2025.

21 Oct. 2025

Adimmune Group Vaccines Listed in WHO Full Vaccine Product List

Adimmune Corporation (TWSE:4142) today announced that three of its vaccines—the seasonal influenza vaccine, tetanus toxoid vaccine, and the enterovirus 71 (EV71) vaccine developed by its subsidiary Enimmune—are now officially listed in the World Health Organization (WHO) Full Vaccine Product List published in September. Inclusion in the WHO list signifies that Adimmune has entered the global public health supply chain, marking a significant milestone for Taiwan’s vaccine industry as its quality and manufacturing capabilities gain recognition from the global health community.

30 Sep. 2025

Adimmune and Enimmune Rush 5,000 Doses of Tetanus Vaccine to Hualien Disaster Zone

Adimmune Corporation (4142) announced today that, in coordination with the Taiwan Centers for Disease Control (CDC) and the Hualien County Health Bureau, it has urgently delivered 5,000 doses of tetanus vaccine to Guangfu Township in Hualien, where residents and volunteers are working intensively on post-disaster cleanup. The donation aims to protect both disaster victims and relief workers from tetanus infections caused by injuries sustained in debris-laden flood zones.

26 Aug. 2025

ANVISA’s GMP Certification Granted to Adimmune Significantly Advances the Progress toward Regulatory Approval in Brazil

Adimmune Corporation (4142) today announced that its Tanzi plant in Taichung has officially received Good Manufacturing Practice (GMP) certification from the Brazilian Health Regulatory Agency (ANVISA). The certification follows an on-site inspection conducted in June, during which ANVISA officials reviewed Adimmune’s influenza vaccine production process.

08 Aug. 2025

Adimmune Enhances Technical Capabilities and Expands CDMO Capacity

Adimmune Corporation (4142) announced today at its investor conference that the company has implemented operational adjustments in response to shifting global political and economic circumstances. In the first half of this year, Adimmune successfully passed inspections by Brazilian ANVISA and EMA respectively. To meet growing demand from clients for additional production capacity, the company’s existing facilities are operating at full load. Adimmune has therefore initiated the installation of a third automated aseptic filling line with an annual capacity of 4 million doses, designed to serve customized, small-batch, and high-value products, and provide end-to-end services from clinical trials to commercial manufacturing—enhancing both capacity and scheduling flexibility.

09 Jul. 2025

Adimmune Adopts QbD to Enhance Process and Product Development

Adimmune Corporation (TWSE: 4142) has been adopting Quality by Design (QbD) practices to align with international standards, enhance its capabilities in process and product development, support international CDMO (contract development and manufacturing organization) projects, and drive new business and technology expansion.

03 Jul. 2024

Enimmune's Enterovirus 71 Vaccine Demonstrates 99.21% Efficacy in Phase III Clinical Trial

Enimmune Corp. (TWSE: 6564), a subsidiary of Adimmune Corporation, today announced the unblinding results of its phase III clinical trial for EnVAX-A71, Enimmune’s enterovirus 71 (EV71) vaccine. The trial demonstrated an impressive vaccine efficacy of 99.21%, establishing EnVAX-A71 as the most effective EV71 vaccine currently available worldwide.